Drug Profile

177-Lu LNC 1004

Alternative Names: 177-Lu LNC-1004

Latest Information Update: 01 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Yantai LNC Biotechnology
Class Antineoplastics; Drug conjugates; Quinolines; Radioisotopes; Radiopharmaceuticals; Small molecules
Mechanism of Action Fibroblast activation protein antagonists; Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

24 Mar 2025 Phase-0 for Thyroid cancer (Second-line therapy or greater) in China (IV) (NCT06898437)
03 Oct 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Singapore (IV) (NCT05723640)
13 Feb 2023 Yantai LNC Biotechnology plans a phase-I trial for Solid tumours (Late-stage disease, Metastatic disease) in Singapore (IV) in March 2023 (NCT05723640)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com